Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Mereo BioPharma Group plc
Every one of those 1 sits in a single category, corporate-law. Of the tracked stories, 1 of 1 also mention Fermi Inc, the most common co-covered peer. They are better corroborated than the beat average, carrying 4 original sources each against 2.8 for the same window. The 5 average consequence score is below the beat benchmark of 6.4 in the same window. We currently track 1 Legal story that mention Mereo BioPharma Group plc, all published on March 5, 2026.
Stories tracked
1
Sources per story
4
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 56 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Mereo BioPharma Group plc. Shared-story counts are live from our verified record — not editorial picks.
Pomerantz Law Firm has issued a series of investor alerts regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These filings highlight a surge in securities litigation targeting volatility in the biotechnology and emerging technology sectors, emphasizing critical lead plaintiff deadlines for affected shareholders.